Pharmafile Logo
Pharmafocus logo
Advanced Search

harvoni

Showing 15 posts of 20 posts found.

gilead-sciences

Gilead to release generic versions of hep C meds over a decade before patent expiry

September 28, 2018
Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma

Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …

News
shutterstock_92671375

US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute

April 26, 2018
Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi

MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …

News
gavel

Long-running, $2.5bn lawsuit swings in Gilead’s favour

February 19, 2018
Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi

The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …

News
gilead-sciences

FDA approves first two antiviral hep C drugs for paediatric patients

April 10, 2017
Sales and Marketing FDA, harvoni, hepatitis C, sovaldi

The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …

News
gilead-sciences

Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies

April 20, 2016
Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir

Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …

News
msd

Gilead must pay MSD $200m in hep C drug patent case

March 29, 2016
Manufacturing and Production, Sales and Marketing Gilead Sciences, MSD, Solvadi, harvoni

A Californian federal jury has ordered Gilead Sciences to pay MSD and Ionis $200 million for infringing on patents relating …

News
gilead-sciences

FDA approves Gilead’s Harvoni in two new indications

February 18, 2016
Research and Development Gilead Sciences, MSD, harvoni, hepatitis C

The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …

News
msd

MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst

February 10, 2016
Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C

The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …

News
Gilead image

FDA expands Gilead’s Harvoni indications for Hep C

November 13, 2015
Sales and Marketing Gilead, Gilead Sciences, harvoni, ledipasvir-sofosbuvir

Gilead’s Harvoni has been approved by the FDA for expanded use in patients with genotypes 4, 5 and 6 chronic …

News

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
Daklinza

NICE restricts access to new hepatitis C treatments

July 29, 2015
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C

NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …

News
Harvoni image

NICE recommends Harvoni for hepatitis C

March 3, 2015
Sales and Marketing Gilead, NICE, harvoni, hepatitis C, ledipasvir-sofosbuvir

NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the …

News
Gilead image

Gilead sales soar on back of hepatitis drugs

February 4, 2015
Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi

The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …

News
Viekirax and Exviera image

AbbVie Hep C combo pill ready for Europe

January 16, 2015
Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi

The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …

News

Pharma industry set for bumper 2015

January 5, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2015, FDA, bumper, harvoni, opdivo, pharma, sovaldi

Industry analysts predict 2015 will be another year of growth for the pharma, after approvals of new drugs soared to …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025